HEALTH | USA
New York governor says case is ‘devastating reminder of what’s at stake’ when vaccine protections are eroded
News ID: 1135 Publish Date : 2026/11/03
HEALTH | USA
New York governor says case is ‘devastating reminder of what’s at stake’ when vaccine protections are eroded
News ID: 1135 Publish Date : 2026/11/03
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
Health
Moderna (MRNA+1.00%) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies.
News ID: 1069 Publish Date : 2026/09/14
